Rotavirus Market

 Market Overview:

The 7 major rotavirus markets are expected to exhibit a CAGR of 8.62% during 2024-2034.

The rotavirus market has been comprehensively analyzed in IMARC's new report titled "Rotavirus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Rotavirus infection is a viral illness that predominantly impacts infants and young children, resulting in gastroenteritis characterized by inflammation in the stomach and intestines. Some of the common symptoms associated with the ailment include severe watery diarrhea, often accompanied by vomiting, fever, abdominal pain, and dehydration. The diarrhea can be frequent and persistent, leading to fluid loss and electrolyte imbalances. In infants and young children, the indications can be particularly severe, potentially causing life-threatening dehydration. Various other signs may include loss of appetite, irritability, general discomfort, etc. The diagnosis of the condition typically involves a combination of clinical evaluation, laboratory testing, and symptom assessment. Healthcare providers may inquire about the patient's medical history and conduct a physical examination to assess symptoms like diarrhea, vomiting, fever, etc. Numerous laboratory procedures, such as enzyme immunoassay (EIA) or rapid antigen detection tests, are commonly used to detect the presence of rotavirus in stool samples. These tests identify the viral antigens and genetic material of the rotavirus. In some cases, a polymerase chain reaction (PCR) test may be performed for confirmation.

The increasing cases of direct contact with an infected person through activities like hugging, kissing, sharing utensils, etc., which can facilitate the transmission of the virus, are primarily driving the rotavirus market. Furthermore, the rising prevalence of numerous associated risk factors, including poor hygiene practices, weakened immune systems, crowded environments, etc., is creating a positive outlook for the market. Apart from this, the escalating utilization of antiemetic medications, such as ondansetron, for reducing nausea and vomiting, thereby improving the patient's ability to tolerate oral rehydration, is also bolstering the market growth. Moreover, several key players are making extensive investments in R&D activities to introduce effective monoclonal antibodies that target specific components of the virus, inhibiting its ability to infect host cells and replicate. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of fecal microbiota transplantation (FMT), which involves manipulating the gut microbiota to improve gut function and reduce the severity of symptoms, is expected to drive the rotavirus market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the rotavirus market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for rotavirus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the rotavirus market in any manner.

Recent Developments:

• In June 2024, Murdoch Children's Research Institute (MCRI) announced that it had signed a non-exclusive licensing arrangement with Incepta Pharmaceuticals to lessen the impact of rotavirus, which is the leading cause of severe diarrhea in newborns and young children globally.

Key Highlights:

• Rotavirus is the most common cause of severe diarrhoea in children globally, resulting in approximately 215,000 deaths each year. More than 90% live in low-income nations in Africa and Asia.
• Rotavirus affects children under the age of five the most, and the first infection is typically the most severe.
• In low-income nations, the median age for the first infection is 6 to 9 months, but in higher-income countries, it is most frequently between 2 and 5 years.
• Before the rotavirus vaccination was released in Australia, the virus infected approximately 10,000 children under the age of five each year.
• Since the vaccination was launched in Australia, child hospital admissions due to rotavirus have decreased by more than 70 percent.

Drugs

ROTARIX is a vaccination designed to prevent rotavirus gastroenteritis caused by G1 and non-G1 strains (G3, G4, and G9) when delivered in a two-dose series. ROTARIX is approved for use in newborns from 6 weeks to 24 weeks of age.

RotaTeq is recommended for the prevention of rotavirus gastroenteritis in newborns and children caused by Types G1, G2, G3, G4, and G9 when provided in a three-dose series to infants aged 6 to 32 weeks. The first recommended dosage of RotaTeq should be administered between 6 and 12 weeks of age.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the rotavirus market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the rotavirus market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current rotavirus marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the rotavirus market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the rotavirus market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the rotavirus market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of rotavirus across the seven major markets?
• What is the number of prevalent cases (2018-2034) of rotavirus by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of rotavirus by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with rotavirus across the seven major markets?
• What is the size of the rotavirus patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of rotavirus?
• What will be the growth rate of patients across the seven major markets?
   

Rotavirus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for rotavirus drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the rotavirus market?
• What are the key regulatory events related to the rotavirus market?
• What is the structure of clinical trial landscape by status related to the rotavirus market?
• What is the structure of clinical trial landscape by phase related to the rotavirus market?
• What is the structure of clinical trial landscape by route of administration related to the rotavirus market?